3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
8
Phase 3
1
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
15
Other hematologic neoplasm
11
Thoracic
7
CNS
6
Sarcoma
5
Breast
5
Dermatologic
4
Plasma cell
3
Gastrointestinal
3
Myeloid
2
Gynecologic
2
Genitourinary
2
Other solid neoplasm
1
Head & Neck
1
Classical hematology
1
Conditions
Mesothelioma, Malignant
1
Mesothelioma
1
Interventions
pembrolizumab
41
Injections
39
toripalimab
23
Nivolumab
22
Cisplatin
19
Pemetrexed
18
Carboplatin
18
Cyclophosphamide
17
Paclitaxel
14
Bevacizumab
14
fludarabine
12
Gemcitabine
11
tislelizumab
10
Ipilimumab
10
spartalizumab
9
Irinotecan
9
atezolizumab
8
Docetaxel
8
Oxaliplatin
7
Leucovorin
7
Fluorouracil
7
Capecitabine
6
sintilimab
5
Interleukin-2
5
Albumin-Bound Paclitaxel
5
130-nm albumin-bound paclitaxel
5
trifluridine tipiracil drug combination
4
sotorasib
4
pazopanib
4
palbociclib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Vorinostat
×
Other solid neoplasm
×
Clear all
NCT01353482
2012-03-22
MESO-02
University College, London
Phase 1/2
Withdrawn